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Gamma-amino butyric acid (GABA) is the major inhibitory neurotransmitter that is known to
be synthesized and released from GABAergic neurons in the brain. However, recent studies
have shown that not only neurons but also astrocytes contain a considerable amount of
GABA that can be released and activate GABA receptors in neighboring neurons. These
exciting new findings for glial GABA raise further interesting questions about the source
of GABA, its mechanism of release and regulation and the functional role of glial GABA. In
this review, we highlight recent studies that identify the presence and release of GABA in
glial cells, we show several proposed potential pathways for accumulation and modulation
of glial intracellular and extracellular GABA content, and finally we discuss functional roles
for glial GABA in the brain.
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INTRODUCTION
Recent experimental evidence suggests that glial cells interact
closely with neurons and play an active role in the brain. In the
central nervous system (CNS), astrocytes, the major type of glia,
make direct contacts with neurons via a structure that has been
defined as the tripartite synapse, in which the astrocytic process
is associated with the pre- and post-synapse areas of neurons
(Araque et al., 1999). Indeed, astrocytes sense neuronal activity
by expressing various receptors for neurotransmitters (Marcaggi
and Attwell, 2004; Schipke and Kettenmann, 2004) and they are
also able to release various transmitters that modulate neuronal
excitability and synaptic transmission (Volterra and Meldolesi,
2005; Perea and Araque, 2010; Zorec et al., 2012). Of the various
transmitters released by glial cells, so-called gliotransmitters, most
of the excitatory transmitters, glutamate, ATP and D-serine have
received much attention (Volterra and Meldolesi, 2005; Fiacco
and McCarthy, 2006; Haydon and Carmignoto, 2006; Oliet and
Mothet, 2006). However, classical inhibitory transmitters are also
released by glial cells and can modulate neuronal activity. Some
studies have suggested that taurine and glycine act as gliotrans-
mitters (Barakat and Bordey, 2002; Hussy, 2002) and some initial
reports showed an accumulation of GABA by glial cells (Barres
et al., 1990; Gallo et al., 1991; Ochi et al., 1993). Despite these
early ideas and recent evidence, the principal CNS inhibitory
transmitter, GABA had not been considered as a gliotransmitter
(Angulo et al., 2008). However, recent studies in primary cultures
(Liu et al., 2000), human astrocytes (Lee et al., 2011b) and
acute brain slices of various brain regions including thalamus,
olfactory bulb and cerebellum (Barakat and Bordey, 2002; Kozlov
et al., 2006; Lee et al., 2010; Jiménez-González et al., 2011)
have demonstrated a robust release of GABA from glial cells.
Moreover, GABA released by glial cells activates the high affinity
GABA receptors to mediate tonic inhibition (Lee et al., 2010; Héja
et al., 2012; Wójtowicz et al., 2013). Glial cells have thus begun
to make their mark not only as GABAceptive cells, but also as
GABAergic cells (Yoon et al., 2012). These exciting new findings
raise questions about the gliotransmitter release mechanism by
glia and the origin and regulation of glial GABA. Furthermore,
alteration of tonic inhibition is found in various pathological
states such as absence seizures, after strokes and in Huntington’s
disease (Clarkson et al., 2010; Pirttimaki et al., 2013; Wójtowicz
et al., 2013). Perhaps these changes in tonic inhibition occur
through glial GABA, a possibility that awaits further investi-
gation. It has recently been reported that tonic GABA release
from reactive astrocytes is enhanced and memory is impaired in
mouse models of Alzheimer’s disease (Jo et al., 2014; Wu et al.,
2014). From initial reports showing GABA accumulation by glial
cells to the more recent studies that give electrophysiological
and pathophysiological evidence of a tonic GABA release that is
mediated by glial GABA, one can safely conclude that glial GABA
modulates neuronal activity and has an important physiological
function. In this review, we present an overview of the cellular
localization of GABA, its production and release mechanisms,
and the potential roles for glial GABA, that all point towards
the new concept of GABA as “a rising gliotransmitter” in the
brain.
CELLULAR LOCALIZATION OF GLIAL GABA IN VARIOUS
BRAIN REGIONS
Initial reports showed that glia contain considerable amounts
of GABA under normal physiological conditions. Astrocytes in
brainstem were labeled with an anti-GABA antibody at the
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level of the soma, in the processes surrounding neurons and in
astrocyte endfeet in contact with blood vessels (Blomqvist and
Broman, 1988). The presence of GABA in glial cells has been
studied extensively in rat optic nerve. In cell cultures of rat optic
nerve, 1 week after plating, O2A-oligodendrocyte progenitor cells,
type 2 astrocytes and differentiated oligodendrocytes were shown
to express GABA (Barres et al., 1990). Gamma-amino butyric
acid was localized using immunofluorescence with an astrocytic
marker, glial fibrillary acidic protein (GFAP), in developing rat
optic nerve from embryonic day 20 to postnatal day 28 (Lake,
1992). A transient increase and gradual decrease of GABA in glial
cells after postnatal day 20 was reported by immunostaining and
high pressure liquid chromatography (HPLC; Ochi et al., 1993).
This study showed the developmental time course of astrocytic
GABA expression in rat optic nerve. Gamma-amino butyric acid
immunostaining was carried out on cultured astrocytes, and on
whole optic nerve and GABA immunoreactivity was localized by
GFAP staining. Gamma-amino butyric acid staining was most
intense in early neonatal optic nerve and became attenuated over
3 weeks of postnatal development. Staining was pronounced in
the astrocyte cell bodies and processes but not in the nucleus.
There was a paucity of GABA immunoreactivity by postnatal day
20, both in cultured cells and in whole optic nerve. A biochemical
assay for optic nerve GABA using HPLC indicated a relatively high
concentration of GABA in the neonate, which rapidly attenuated
over the first three postnatal weeks (Ochi et al., 1993). Gamma-
amino butyric acid immunoreactivity was also observed in glial
cells from the adult rat cerebellum (Martínez-Rodríguez et al.,
1993). Both GABA- and Glutamic acid decarboxylase (GAD)-
immunoreactivities were observed within dendrites and glial cells
using different antisera obtained from rabbits immunized with
GABA, baclofen and GAD. These results suggested a possible
extrasynaptic release of GABA. However, these early findings had
been almost forgotten by brain research scientists until recently
(Angulo et al., 2008). We ourselves have recently reported strong
GABA immunoreactivities in Bergmann glial cells and lamellar
astrocytes of the mouse cerebellum using a commercially available
anti-GABA antibody in GFAP-GFP transgenic mice (Lee et al.,
2010). We have suggested that the amount of glial GABA is
variable depending on different brain regions (Figure 1) and
that it positively correlates with the degree of tonic inhibition
current (Yoon et al., 2011). For example, glial GABA as evidenced
by GABA immunoreactivity was high in the cerebellum and
correlated well with a significant level of tonic inhibition current,
whereas GABA immunoreactivity was very low in the hippocam-
pus CA1 region with a low level of tonic inhibition current
(Yoon et al., 2011). These results suggested that some regulatory
mechanism exists to control the level of intracellular GABA in
astrocytes. More recently, GABA immunoparticles were localized
by electron microscopy in synaptic terminals with symmetric
synapses as well as in astrocytes from CA1 and CA3 areas, the stra-
tum radiatum and in the dentate gyrus (Le Meur et al., 2012). This
would seem to indicate that a large proportion of hippocampal
astrocytes contain the inhibitory transmitter GABA. In addition,
immunoreactivity for GABA, GAD65, GAD67 and Bestrophin-
1 (Best1), a GABA-permeable channel, has been observed in
the meninges and the choroid plexus, implying a non-neuronal
source for GABA in the developing mouse brain (Tochitani and
Kondo, 2013).
PRODUCTION OF GABA IN GLIAL CELLS
With respect to the original source of glial GABA, we wonder
whether this GABA is synthesized within cells or taken up from
the extracellular space. If a glial cell has its own biosynthetic
pathway for GABA, then glial GABA content can be modulated
by innate molecular factors and can be independent of neuronal
activity. However, if glial GABA comes only from uptake of extra-
cellular GABA via GABA transporters, it should be solely depen-
dent on activity-dependent neuronal GABA release, although this
explanation might not explain the varying amount of glial GABA
in different brain regions (Yoon et al., 2011). Actually, tonic GABA
release from glia in cerebellum is known to be independent of
neuronal activity and neuronal GABA release (Rossi et al., 2003).
Therefore, it is likely that multiple pathways, rather than one
single route, are involved in the biosynthesis and regulation of
glial GABA.
EVIDENCE FOR GAD AS A BIOSYNTHETIC ENZYME FOR GLIAL GABA
Immunoreactivity for the GABA synthesizing enzyme GAD was
prominent in neonates but attenuated with development. This
was especially the case for GAD67, which was observed in
glial cells of neonatal rats but decreased after postnatal day
21. The other isoform, GAD65, was not present in these cells.
GABA and GAD are clearly localized in astrocytes of optic nerve
and their expression is transient during postnatal development
(Ochi et al., 1993). In mature rat cerebellar glia, both GABA
and GAD immunoreactivities were found (Martínez-Rodríguez
et al., 1993) and more recently, GAD immunoreactivity was
reported in astrocyte end feet of the human cerebellar cortex
using immunohistochemistry and electron microscopy. In these
studies, GAD immunoreactivity was observed in nerve terminals
that are in direct contact with the astrocyte perivascular sheath
of capillaries and also within astroglial perivascular end feet
and endothelial cells (Benagiano et al., 2000). These findings
provide further insight into the GABAergic synapse circuitry
of the human cerebellar cortex and the detection of “vascular”
GAD immunoreactivities suggests that GABAergic mechanisms
may regulate cerebellar microvessel function (Benagiano et al.,
2000). Glutamic acid decarboxylase was also observed in cultured
human astrocytes (Lee et al., 2011b). This work suggested that the
intracellular GABA level is about 2.32 mM in untreated cultures
of human astrocytes. The authors exported GABA into the culture
medium so that an intracellular-extracellular gradient of 3.64-fold
was reached. Treatment with inhibitors of the GABA transporters
GAT-1, GAT-2, and GAT-3, significantly reduced GABA export
in a calcium-independent manner. These findings confirmed the
existence of GAD within glial cells but they also emphasized the
contribution from GABA transporters in establishing glial GABA
content.
EVIDENCE FOR MONOAMINE OXIDASE B (MAOB) AS A KEY
BIOSYNTHETIC ENZYME FOR GLIAL GABA
Contrasting reports suggest that GABA is produced by another
biosynthetic pathway, which is independent of GAD activity,
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FIGURE 1 | Presence of GABA in glial cells in various brain regions
of GFAP-GFP mice. Gamma-amino butyric acid is present in the
cerebellum, hippocampus and thalamus, though the GABA-containing
portion of the glial cell differs between brain regions. Gamma-amino
butyric acid does not co-localize much with GFAP-GFP staining in the
hippocampus compared to the cerebellar cortex.
but that requires putrescine as an initial substrate. This was
first suggested in mouse and fish brain (Seiler and Askar, 1971;
Seiler et al., 1973). In trout brain, following intraperitoneal and
intracerebral injections of [1,4-14C]putrescine.2HCl, GABA was
shown to be formed in vivo, via a pathway that does not have
glutamic acid as an intermediate. After intracerebral injections of
[1-14C] GABA, a half-life of 7 h was obtained for GABA. This slow
turnover rate for GABA in trout brain may help to further explain
the ineffectiveness of the glutamate decarboxylase inhibitors in
lowering the GABA content of fish brain within a few hours (Seiler
et al., 1973). Putrescine concentrations can be quantitatively
estimated in tissue and have been determined in mouse brain and
liver (Seiler and Askar, 1971). This polyamine involved pathway
for GABA synthesis was tested in mouse neuroblastoma cells
(Kremzner et al., 1975). Polyamine metabolism in cultured mouse
neuroblastoma cells was studied with the aim of synthesizing
GABA from putrescine and putreanine from spermidine. It was
shown that neuroblastoma cells, in the presence of a complete
culture medium containing calf serum, readily metabolized [14C]
putrescine to GABA. The rate of synthesis is similar to that for
the synthesis of spermidine from putrescine. In the absence of
serum, the conversion of putrescine to GABA is minimal. In
the presence of serum, GABA formation is completely inhibited
by the diamine oxidase inhibitor aminoguanidine. Synthesized
GABA is not readily metabolized to succinate or homocarno-
sine. Mouse neuroblastoma cells metabolized [14C] ornithine to
putrescine, GABA, and spermidine. Spermidine was metabolized
to putrescine, putreanine and spermine (Kremzner et al., 1975).
This is the monoamine oxidase pathway of putrescine (Figure 2).
Cultured O2A glial progenitor cells of the optic nerve were able
to synthesize GABA from putrescine. In these cells, there is no
detectable GAD expression, but a strong GABA immunoreactivity
was seen and HPLC measurements revealed an increased quan-
tity of GABA in a putrescine-enriched medium (Barres et al.,
1990). Glial cell GABA may also be involved in some pathological
conditions. A comparison between GABA formation in primary
cultured astrocytes from epileptic and normal mice showed that
the rate of GABA production from radioactive putrescine was
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FIGURE 2 | Pathway showing GABA synthesis from putrescine.
Astrocytes synthesize GABA from putrescine via monoamine oxidation.
PAT: putrescine acetyltransferase; MAOB: monoamine oxidase B; ALDH2:
aldehyde dehydrogenase 2.
four times higher in epileptic than in normal mice (Laschet et al.,
1992). Moreover, after transiently occluding the carotid arteries
of adult gerbils, the GFAP immunoreactivity increased in the
damaged forebrain tissue and reactive astrocytes were labeled with
GABA, but not with GAD antisera. This GABA immunoreactivity
persisted in ischemic animals for up to 3 months without GAD
activity (Lin et al., 1993). It has recently been reported that
glial monoamine oxidase B (MAOB) is the GABA synthesizing
enzyme that mediates tonic GABA release. In the cerebellum
and striatum of adult mice, general gene-silencing or knockout
of MAOB, or treatment with selegiline, eliminated tonic GABA
currents recorded from granule neurons and medium spiny neu-
rons. Glial specific rescue of MAOB resulted in a complete rescue
of tonic GABA currents. These results identify MAOB as a key
synthesizing enzyme of glial GABA, which is released via the Best1
channel to mediate tonic inhibition in the brain (Yoon et al.,
2014).
In summary, there is accumulating evidence for the presence
of a GAD or putrescine-derived pathway, suggesting that there
are multiple possible routes for the synthesis of glial GABA, as
well as the GABA accumulation occurring by uptake through
GABA transporters. Until now, most of these findings have been
obtained from in vitro experiments and cell culture systems.
However, to clarify the GABA production mechanism, in vivo
studies are required to confirm the presence of putrescine and to
show that MAOB is a key enzyme for GABA production.
RELEASE OF GABA FROM GLIAL CELLS
The synaptic release of GABA and the functional consequences
of GABA receptor activation have been extensively studied.
The vesicular release of GABA from the axon terminals of
inhibitory neurons, which affect nearby postsynaptic targets as
well as some extrasynaptic receptors, is a well-established con-
cept of GABAergic signaling. So, questions arising are: Can
glial cells release GABA, like neurons? How is glial GABA
released? How do glial cells differ in their release of GABA
compared to neurons? There is increasing evidence to show
that GABA is indeed released from glial cells. Several reports
suggest that, unlike neurons, glial GABA can be released via
unconventional pathways. For example, GABA may be released
from glial cells by the reversal of transporters, or by non-
vesicular release mechanisms. We shall review here the recent
findings regarding such unconventional mechanisms of glial
GABA release and shall discuss the physiological significance of
these mechanisms.
EVIDENCE OF GABA RELEASE FROM GLIAL CELLS
Classically, extracellular GABA was thought to be taken up by
GABA transporters expressed on glial cells. Consequently, we
would expect glial cells to contain considerable amounts of
GABA arising from this uptake. However, several studies provide
convincing evidence for the active release of GABA from glial
cells. Glioma cell lines have been shown to excrete concentrated
GABA into the extracellular medium. This is consistent with
the theory that, in the brain, the untransformed counterparts
of these glial tumor cells may have the capacity to control the
extracellular concentration of neuroactive molecules, especially
GABA (Schrier and Thompson, 1974). In cultured hippocam-
pal glial cells, Jow et al. (2004) observed that the conditioned
medium contained an inhibitory factor that can hyperpolarize
and suppress neuronal activity. They investigated this inhibitory
factor using biochemistry, electrophysiology, pharmacology, and
mass spectrometry. Mass spectrometry analysis of conditioned
medium revealed peaks that are identical to those for GABA.
A concentration of up to 500 µM GABA was found in con-
ditioned medium from glial cultures, but no GABA was found
in conditioned medium from neuronal cultures. According to
these findings, hippocampal glial cells make much more GABA
than cortical glia (Jow et al., 2004). To overcome the limita-
tions of culture studies, GABA release from glial cells was then
detected and characterized in acute brain slices. In the cerebellum,
whole-cell patch clamp recordings of Bergmann glia showed
an electrogenic GABA efflux that activated neighboring GABAA
receptors (Barakat and Bordey, 2002). These authors suggested
that the GABA efflux was mediated by a reversal of the GAT-1
expressed in glial cells (Barakat and Bordey, 2002). In acute slices
of olfactory bulb, whole-cell recordings from neurons revealed
a spontaneous slow GABAA receptor-mediated current (Kozlov
et al., 2006). These studies demonstrated that the release of GABA
by astrocytes caused a long lasting and synchronous inhibition of
mitral and granule cells in the olfactory bulb (Kozlov et al., 2006).
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This group also observed that astrocytes are capable of releas-
ing glutamate, as well as GABA, leading to a selective activa-
tion of granule cell NMDA receptors. Therefore, they suggested
that by releasing both excitatory and inhibitory gliotransmitters,
astrocytes are capable of a complex modulatory control of the
olfactory network through neuron-glia interactions (Kozlov et al.,
2006).
MECHANISM OF GABA RELEASE FROM GLIAL CELLS
Various candidate pathways have been suggested to account for
the mechanism of tonic GABA release from glia. Three possibili-
ties seem to be the most likely: (i) vesicular release; (ii) a rever-
sal of GABA transporters; (iii) non-vesicular channel-mediated
release. To date however, there is no clear evidence for vesicular
release. The lack of GABA-containing synaptic vesicles makes it
unlikely that glial cells utilize a vesicular release mechanism. The
remaining two possible mechanisms, reversal of transporters and
channel-mediated release are the most often suggested. In cerebel-
lar slices, the GABA transporter has been suggested as a candidate
mechanism for GABA release (Barakat and Bordey, 2002). It
was shown that with 10 mM GABA in the recording pipette,
GABA transporters expressed in Bergmann glia operated in the
reverse mode, leading to a release of GABA into the extracellular
space, subsequently activating GABAA receptors tonically on the
same cell. In contrast, the tonic activation of GABAA receptors
expressed in cerebellar granule cells of adult rats has been shown
to be an action potential-independent and non-vesicular release
(Wall and Usowicz, 1997; Mitchell and Silver, 2003; Rossi et al.,
2003). Despite this finding, a reversal of the GABA transporter is
also suggested by Richerson and Wu (2003) and Lee et al. (2011a).
In particular, GAT-2/3 have been considered as an alternative
mechanism of GABA release from astrocytes (Héja et al., 2012;
Unichenko et al., 2013). Heja et al. demonstrated that GABA
is released from astrocytes by the reverse action of glial GABA
transporter and that GABA release can be prevented by blocking
glutamate uptake with an inhibitor. They argued that the released
GABA contributes to the tonic inhibition of neurons in a network
activity-dependent manner. Unichenko et al. (2013) reported a
role for GAT-2/3 in developmental stages. However, some of
these studies were performed with culture systems or under non-
physiological conditions. Moreover, the non-vesicular release and
action potential-independent release of GABA were shown to
contribute to tonic inhibition and tonic GABAA conductance in
other brain areas, including the cerebellum, olfactory bulb and
hippocampus (Brickley et al., 1996; Kozlov et al., 2006; Glykys and
Mody, 2007). Persistent and slow GABAA receptor-mediated exci-
tatory currents activated by a non-synaptic release of GABA have
been reported in rat embryonic and early postnatal hippocampal
slices. This tonic and slow current was induced by a Ca2+-
and SNARE protein-independent release of GABA, suggesting a
non-conventional and non-vesicular release during development
(Demarque et al., 2002). These researchers reported the presence
of tonic, spontaneous, and evoked currents in embryonic and
neonatal CA1 neurons mediated primarily by the activation of
GABAA receptors. These currents persist in the presence of cal-
cium channel blockers or botulinum toxin and are observed in
Munc18-1-deficient mice in which vesicular release is abolished.
Of interest to note, is that this paracrine communication is mod-
ulated by glutamate but not by GABA transporters (Demarque
et al., 2002). One study performed in a cell line derived from
type 2 astrocytes showed that the release of GABA is sensitive to
inhibitors of anion channels (Wang et al., 2002). Recently, we have
identified and demonstrated a channel-mediated tonic GABA
release from glia (Lee et al., 2010), a non-vesicular and non-
conventional mechanism for GABA release in cerebellar slices
under physiological conditions. We found that GABA permeates
directly through the Ca2+-activated anion channel, Best1, to
yield GABA release and that tonic inhibition is eliminated by
gene silencing of Best1. Using immunohistochemistry, cerebellar
Bergmann glial cells and lamellar astrocytes were seen to express
both GABA and Best1, and selective expression of Best1 was seen
in glial cells. After preventing the general expression of Best1
by Best1 specific shRNA, tonic inhibition was fully rescued by
glia specific flanking of the Best1 specific shRNA (Lee et al.,
2010).
The precise mechanism underlying tonic GABA release has
been difficult to elucidate because this GABA release exhibits
several puzzling features that are quite different from those
exhibited by the conventional, phasic release of GABA. Our
proposed mechanism of channel-mediated release via the Best1
channel can account for each of these properties in cerebellar
slices. First, the non-vesicular nature of tonic GABA release is
consistent with a channel-mediated mechanism. Second, inde-
pendence from neuronal activity can be explained by the glial
origins of tonic inhibition. Finally, the apparent lack of depen-
dence on external Ca2+ arises from substantial activation of
Best1 at resting levels of intracellular Ca2+, leading to consti-
tutive release of GABA at such intracellular Ca2+ levels (Lee
et al., 2010). This unprecedented mechanism is consistent with
several previous reports that have suggested a non-vesicular and
action potential-independent release of GABA (Brickley et al.,
1996; Kozlov et al., 2006; Glykys and Mody, 2007) and a well-
documented Ca2+- and SNARE protein-independent release of
GABA during development (Demarque et al., 2002). A further
recent report on GABA release from reactive astrocytes in the
hippocampus, supports a role for Best1 channels in the release
of GABA from glial cells and has implications not only for
physiological states but also for pathological conditions (Jo et al.,
2014).
A recently published report by Diaz et al. (2011) raised con-
tradictory evidence against our model of Best1-mediated tonic
GABA release. However, after examining the paper in detail, we
found that the authors provide only pharmacological evidence
using NPPB as a blocker of Best1 channel (Diaz et al., 2011). It
is important to note that NPPB is notorious for having many
side effects. Authors claimed that NPPB enhanced tonic GABA
current within 4–5 min, instead of blocking. We also found that
NPPB initially increased tonic GABA current, but if we waited
longer time period of about 10 min, we saw a block by NPPB
(see Figure Sf9a and S9d of Lee et al. (2010)). Thus, if the
authors applied NPPB for longer time, they would have seen the
block by NPPB, as we observed previously. Nevertheless, this was
precisely why we utilized cell-type specific gene-silencing method
by lentiviral shRNA (Lee et al., 2010), which is far more specific
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to Best1 than NPPB. Diaz et al. (2011) did not use any of genetic
approaches. Therefore, their claim as shown in the title of their
paper, “Best1 channels are insensitive to ethanol and do not
mediate tonic GABAergic currents in cerebellar granule cells,” was
an overstatement.
THE ROLE OF GLIAL GABA RELEASE IN THE BRAIN
SPECIAL ROLES OF GLIAL GABA DURING DEVELOPMENT
Depolarization of neurons by astrocytic GABA was first reported
in rat embryonic hippocampal neuronal cell cultures (Liu
et al., 2000). In this study, neurons exposed to astrocyte-
conditioned medium (ACM) showed a highly significant increase
in a bicuculline-sensitive persistent GABAA receptor-mediated
current, whereas this tonic activation was absent in neurons
bathed in normal medium (Liu et al., 2000). These findings
implied that astrocyte-released GABA intensifies GABAergic
autocrine/paracrine signaling at GABAA receptor/Cl− channels,
thus effectively depolarizing differentiating hippocampal neurons
near the equilibrium potential of Cl−. The same study also found
that ACM could rescue neurite outgrowth in embryonic hip-
pocampal and cortical neurons that had been treated with 3-MPA
(to block GAD-derived GABA synthesis), via bicuculline- and
nitrendipine-sensitive mechanisms. These results indicated that
astrocyte-derived GABA provides a critical depolarizing signal
that indirectly stimulates Ca2+ entry through voltage-gated Ca2+
channels, thereby supporting neuritogenesis (Liu et al., 2000).
In a separate study, GABA excitation has been shown in rat
embryonic and immature hippocampal slices (Demarque et al.,
2002). However, during early development, in the marginal zone
of mouse neocortex, GABA has been shown to be released via
GABA transporters, GAT-2/3, whereas glutamate transporters
operate in the uptake mode (Unichenko et al., 2013). This implies
that GABA release by glia is essential for development and also
that alteration of glial GABA during development can cause
neurodevelopmental disorders.
INHIBITORY FUNCTION OF GLIAL GABA IN THE MATURE AND
DISEASED BRAIN
Previous reports suggest that glial GABA has a special role in
the developing brain, though in the more mature brain, glial
GABA appears to have an inhibitory effect. Based on numerous
studies, we can infer that glial cells must be the source of an
inhibitory transmitter responsible for tonic GABAA receptor-
mediated currents. For example, glial cells can release GABA into
the extracellular space and tonically activate high-affinity GABAA
receptors by volume transmission in cerebellum (Rossi et al.,
2003; Lee et al., 2010) maintaining a persistent inhibitory tone
in these brain regions. Glial GABA has also been seen to act on
GABAB receptors (Benedetti et al., 2011). Tonic inhibitory tones
have recently been reported in other brain regions including the
cortex (Wlodarczyk et al., 2013) and the hippocampus (Pavlov
and Walker, 2013; Song et al., 2013). However, phasic GABA
released from presynaptic terminals of neurons activates low-
affinity synaptic GABAA receptors. The extracellular tonic GABA
is estimated to be around 160 nM (Santhakumar et al., 2006;
Lee et al., 2010), whereas that of phasic GABA at the synap-
tic junctions is around 3 mM (Mozrzymas et al., 2003). The
synaptically released GABA is constantly taken up by the high
performance GABA transporters that are ready for uptake near
the synapses. These GABA transporters serve as a barrier that
separates the extrasynaptic space and synaptic junctions. The high
affinity extrasynaptic GABAA receptors are non-desensitizing and
have a half-maximal effective concentration (EC50) of GABA in
the range of 0.3–0.7 µM, whereas synaptic GABAA receptors are
strongly desensitizing and have an EC50 of GABA in the range
of 6–14 µM. There is a clear forty-fold difference in the affinity
of GABAA receptors for GABA. To sum up, different locations,
extrasynaptic or synaptic, different extracellular concentrations
of GABA, and differing degrees of desensitization and sensitivity
of GABAA receptors to GABA, make these two distinct GABAA
receptor activation modes, tonic and phasic, function quite dif-
ferently and independently of each other. Therefore, tonic GABA
serves to inhibit target neurons on a slow time scale, whereas
phasic GABA serves to inhibit target neurons on a fast time scale
in the physiological state.
Indeed, tonic inhibition has been reported to have diverse
physiological and pathological roles in the CNS. Blocking tonic
inhibition with furosemide was shown to increase the firing fre-
quency of cerebellar granule cells (Hamann et al., 2002). Alcohol,
by potentiating extrasynaptic GABAA, was shown to enhance
tonic inhibition in the cerebellum and impair motor behavior
(Hanchar et al., 2005). Enhanced tonic inhibition in the thalamus
was observed in typical genetic and pharmacological absence
seizure models (Cope et al., 2009). Reducing excessive GABA-
mediated tonic inhibition was shown to promote functional
recovery after stroke in the motor cortex (Clarkson et al., 2010).
Alterations in tonic GABAA receptor-mediated signaling was not
only found in absence seizure models, but also in temporal lobe
epilepsy (Pavlov and Walker, 2013). Very recently, an enduring
loss of tonic but not phasic GABAA receptor-mediated currents
was shown to critically contribute to the prolonged amygdala
disinhibition subsequent to chronic stress exposure (Liu et al.,
2014).
There are several lines of evidence to show that GABA
release from glia is directly associated with pathological con-
ditions. One recent report found an enhanced tonic inhibi-
tion in absence epilepsy and observed a dysfunction in the
astrocytic GABA transporter, GAT-1 in absence seizure models
(Pirttimaki et al., 2013). Reduced tonic inhibition was reported
in mouse models of Huntington’s disease, resulting from a loss
of astrocytic GABA release (Wójtowicz et al., 2013). Another
study reported anti-inflammatory actions of GABA from glia
by modulating microglial activity in human astrocyte cultures
(Lee et al., 2011b). More recently, two studies from indepen-
dent research groups showed that reactive astrocytes abnor-
mally release GABA to impair memory in mouse models of
Alzheimer’s disease (Jo et al., 2014; Wu et al., 2014). These
recent studies propose a novel and crucial role for glial GABA
as the major inhibitory gliotransmitter in many pathological
conditions.
CONCLUDING REMARKS
This review highlights the compelling evidence accumulat-
ing for GABA synthesis and release from glia and reveals
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that this released GABA plays an important role in brain
function. Several mechanisms are proposed for glial GABA
biosynthesis and release. Further research is needed to sub-
stantiate the precise mechanism for each process. However,
it is clear that glial GABA is present in various brain
regions and has potentially important roles in each region.
Finally, we need to develop new genetic animal models, more
detailed characterizations of the various pathological conditions
associated with glial GABA and perform more detailed inves-
tigations of the regulation of glial GABA in order to eluci-
date the true nature of the in vivo functions of GABA as a
gliotransmitter.
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